BioCentury | Oct 1, 2019
Company News

Biogen turns to R&D vet as Ehlers exits

...tenure are now starting Phase III trials, including glibenclamide to treat stroke, antisense oligo tofersen (BIIB067...
BioCentury | May 2, 2019
Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

...Pharmaceuticals Inc. (NASDAQ:IONS). Among ALS patients with a confirmed SOD1 mutation, 100 mg tofersen (formerly BIIB067...
...Tumor necrosis factor receptor superfamily member 17; SOD1 - Superoxide dismutase 1 Brian Moy, Assistant Editor bb2121 BIIB067, IONIS-SOD1Rx GKT831...
BioCentury | Apr 24, 2019
Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

...opicinumab in MS; gosuranemab (BIIB092) in progressive supranuclear palsy; BIIB054 in Parkinson's disease; and tofersen (BIIB067...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Neurology

...for Wilson disease and preclinical testing for ALS. Ionis Pharmaceuticals Inc. and Biogen Inc. have IONIS-SOD1Rx...
BioCentury | Dec 7, 2018
Company News

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

...Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals...
...collaboration. The partners said that in a Phase I trial, the highest tested dose of BIIB067...
...$56.05. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Business: Neurology Jennie Walters BIIB067, IONIS-SOD1Rx Biogen...
BioCentury | Dec 6, 2018
Company News

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

...Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals...
...collaboration. The partners said that in a Phase I trial, the highest tested dose of BIIB067...
...placebo (p=0.002). Biogen added $3.97 to $326.70 Thursday; Ionis was up $0.05 to $56.05. Jennie Walters BIIB067, IONIS-SOD1Rx Biogen Ionis...
BioCentury | Aug 17, 2018
Clinical News

SOD1 antisense oligonucleotide improves survival in ALS model

...1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) showing that a single bolus dose of intrathecal IONIS-SOD1Rx (BIIB067...
...by up to 64 days compared with vehicle. In a mouse model of the disease, IONIS-SOD1Rx...
...NASDAQ:IONS), Carlsbad, Calif. Product: IONIS-SOD1Rx (BIIB067) Business: Neurology Indication: Treat amyotrophic lateral sclerosis (ALS) Brian Moy BIIB067, IONIS-SOD1Rx Biogen...
BioCentury | May 12, 2016
Translation in Brief

PET projects

...in Phase I testing for PD. Biogen and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) have IONIS-SOD1Rx ( BIIB067...
BioCentury | Mar 24, 2016
Translation in Brief

Biogen buddies up

...identify genetic risk factors for ALS and develop tailored therapies. The company has BIIB067 ( IONIS-SOD1Rx...
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...radical scavenger cerebral neuroprotectant Phase I Biogen Inc. (NASDAQ:BIIB) / Ionis Pharmaceuticals Inc. (NASDAQ:IONS) IONIS-SOD1Rx (BIIB067...
Items per page:
1 - 10 of 10